NASDAQ:KZR - Kezar Life Sciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: 107.61 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$5.78
▲ +0.14 (2.48%)
1 month | 3 months | 12 months
Get New Kezar Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KZR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KZR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$12.00
▲ +107.61% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Kezar Life Sciences in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 107.61% upside from the last price of $5.78.

Buy

The current consensus among 1 polled investment analysts is to buy stock in Kezar Life Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/15/2021HC WainwrightReiterated RatingBuy$12.00High
i
9/22/2020HC WainwrightReiterated RatingBuy$12.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
8/6/2020HC WainwrightReiterated RatingBuy$12.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
6/14/2020CowenReiterated RatingOutperformLow
i
6/14/2020Wells Fargo & CompanyReiterated RatingOverweight ➝ Market Perform$18.00Low
i
6/4/2020HC WainwrightReiterated RatingBuy$9.00 ➝ $12.00High
i
5/5/2020HC WainwrightReiterated RatingBuy$15.00 ➝ $9.00Medium
i
3/13/2020William BlairReiterated RatingBuyHigh
i
Rating by Matt Phipps at William Blair
3/13/2020Wells Fargo & CompanyLower Price TargetOverweight$30.00 ➝ $18.00High
i
11/6/2019CowenReiterated RatingBuyMedium
i
10/21/2019HC WainwrightReiterated RatingBuy$15.00Medium
i
Rating by R. Selvaraju at HC Wainwright
8/8/2019CowenReiterated RatingBuyHigh
i
7/29/2019HC WainwrightInitiated CoverageBuy$15.00Low
i
Rating by R. Selvaraju at HC Wainwright
3/12/2019William BlairReiterated RatingOutperformHigh
i
7/16/2018Jefferies Financial GroupInitiated CoverageBuy$23.00High
i
7/16/2018CowenInitiated CoverageOutperformHigh
i
7/16/2018Wells Fargo & CompanyInitiated CoverageOutperform$30.00High
i
7/16/2018William BlairInitiated CoverageOutperformHigh
i
Rating by M. Phipps at William Blair
(Data available from 6/14/2016 forward)
Kezar Life Sciences logo
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is based in South San Francisco, California.
Read More

Today's Range

Now: $5.78
$5.66
$5.96

50 Day Range

MA: $5.69
$4.93
$6.46

52 Week Range

Now: $5.78
$4.24
$7.40

Volume

214,002 shs

Average Volume

255,259 shs

Market Capitalization

$277.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.34

Frequently Asked Questions

What sell-side analysts currently cover shares of Kezar Life Sciences?

The following Wall Street sell-side analysts have issued reports on Kezar Life Sciences in the last twelve months: Cowen Inc, HC Wainwright, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for KZR.

What is the current price target for Kezar Life Sciences?

1 Wall Street analysts have set twelve-month price targets for Kezar Life Sciences in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 103.4%. HC Wainwright has the highest price target set, predicting KZR will reach $12.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $12.00 for Kezar Life Sciences in the next year.
View the latest price targets for KZR.

What is the current consensus analyst rating for Kezar Life Sciences?

Kezar Life Sciences currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KZR will outperform the market and that investors should add to their positions of Kezar Life Sciences.
View the latest ratings for KZR.

What other companies compete with Kezar Life Sciences?

How do I contact Kezar Life Sciences' investor relations team?

Kezar Life Sciences' physical mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 650-822-5600 and its investor relations email address is [email protected] The official website for Kezar Life Sciences is www.kezarlifesciences.com.